Basal Cell Carcinoma by Tomasz Dębski et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Basal Cell Carcinoma 
Tomasz Dębski, Lubomir Lembas and Józef Jethon 
Department of Plastic Surgery, 
The Medical Centre of Postgraduate Education in Warsaw 
Poland 
1. Introduction 
Neoplastic lesions of the skin are among the most common human malignancies. They 
originate from different skin tissues and structures such as: 
 epidermis 
 skin appendages (hair follicles, sebaceous glands, eccrine sweat glands, apocrine sweat 
glands) 
 pigment cells (melanocytes) 
 mesenchymal structures (fibrous tissue, fatty tissue, blood and lymphatic vessels, 
muscles)  
 nerves and APUD cells of the neuroendocrine system  
 lymphatic system cells. 
The vast majority of neoplasms originating from the above skin structures are benign 
neoplasms. They are characterised by slow local growth and lack of intensive tissue damage. 
The remaining part of neoplastic lesions consists of skin malignancies including carcinomas 
(originating from the epidermis and skin appendages), melanomas (originating from 
pigment cells), lymphomas (originating from the lymphatic system cells) and sarcomas 
(originating from other skin cells) Other classification of malignancies is as follows: 
Non-Melanoma Skin Cancer (NMSC) and Melanoma Malignum (MM.) NMSC include 
skin cancers (96% of skin malignancies), lymphomas and sarcomas (1% of skin 
malignancies.) The remaining 3% is MM which is characterised by high malignancy and 
accounts for 75% of all deaths due to skin neoplasms (Kordek et al., 2004 ; The Burden of 
Skin Cancer, 2008). 
Despite the fact that there are different classifications available in literature, one thing that 
does not change is that cancer is the most common histopathological form of malignancies. 
Almost all skin cancers originate in the epidermis. Cancers arising in the skin appendages 
constitute a very low per cent. From a histological point of view the epidermis is stratified  
epithelium with several layers of cells. Depending on an epidermal layer (the basal cell or 
squamous cell layer) skin cancers are divided into: 
 Basal Cell Carcinoma (BCC) originating from the basal cell layer of the epidermis and 
sheaths of hair follicles. It constitutes 80% of all skin cancers.  
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
 Squamous Cell Carcinoma (SCC) originating from cells in the Malpighi layer and it 
accounts for 20% of skin cancers (Kordek et al.,. 2004). 
Although both BCC and SCC originate from the epidermis, their biology is completely 
different and therefore they cannot be discussed together. For that reason the authors of this 
review have decided to present problems associated only with one of them, namely BCC. 
BCC is of the most common human malignancies, and its incidence has been rising within 
the last decade (Preston & Stern, 1992). Although it is not life-threatening, its local malignant 
features, especially in the area of the face may cause significant functional and aesthetic 
disturbances what has a profound effect on the quality of life of patients. If BCC is left 
untreated, it can infiltrate not only adjacent tissues but also bones and even deeper 
structures like brain (Franchimont, 1982). Moreover, extremely rare distant metastases of 
this neoplasm have been described (Lo et al., 1991). 
BCC diagnostics and treatment is managed by physicians of different specialities 
(dermatologists, plastic surgeons, general surgeons, oncologists, ophthalmologists, ENT 
specialists, and even general medicine specialists) who promote therapeutic options which 
are closely related to their specialities and are often controversial. Available literature 
reports different therapeutic methods including non-invasive techniques such as local 
application of Imiquimod-containing ointments (Mark et al., 2001), photodynamic therapy 
(Clark et al., 2003), radiation therapy (Kwan et al., 2004), CO2 laser ablation (Nouri et al., 
2002), cryosurgery (Giuffrida et al., 2003), cautery (Spiller WF & Spiller RF, 1984) and 
curettage (Reyman, 1985) or surgical excision of a lesion with a margin of clinically normal 
surrounding tissues (Walker & Hill, 2006). 
Functional and aesthetic results, treatment efficacy, side effects and effects on the quality of 
life are different and depend on the method that has been used.  
Method selection depends on lesion morphological features and patient’s condition and 
preferences. The majority of methods to treat BCC described so far may be used only in 
some, highly selected cases. The only universal method that can be used to treat all cases of 
BCC is surgical excision with a margin of clinically normal surrounding tissues.  
Due to high efficacy of this method, its versatility, good functional and aesthetic results, low 
risk of complications, availability, low costs, and what is the most important, the ability of 
postoperative histological assessment of excision completeness, surgical treatment is 
currently the most common method to treat BCC. 
2. Epidemiology 
Among all human malignancies skin cancer occurs the most frequently and it accounts for 
almost 1/3 of all detectable neoplasms (Kordek et al., 2004). Despite the fact that since the 
early 1990s the global incidence of neoplasms has been decreasing the rate of incidence of 
skin cancer has been rising and it is estimated to be 10-15% annually, what is almost ten 
times higher than the population growth rate (Cole & Rodu, 1996; Kordek et al., 2004; Parkin 
et al., 1999). It has to be emphasised that there are no precise records especially with regard 
to BCC and therefore epidemiological data are often understated and not included in global 
lists of incidence rates of neoplasms (Kordek et al., 2004).  
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Only in the USA, more than one million cases of skin cancers are detected every year 
(American Cancer Society, 2008). It is the number almost equal to the number of all other 
cancers detected annually in this country (American Cancer Society, 2006). It is estimated 
that one out of five Americans will develop skin cancer (American Cancer Society, 2008), 
and in almost half of 65-year-olds this cancer will occur at least once in their lives (Robinson, 
2005). 
Although the data presented above regard all cases of skin cancers it can be assumed that 
they reflect BCC epidemiology to a large extent, as BCC accounts for almost 80% of all cases 
of skin cancers (Kordek et al., 2004). 
 Global statistics unanimously indicate that BCC is one of the most common neoplasms in 
Europe, Australia and the USA (Miller & Weinstock, 1994), and the number of new cases is 
increasing every year (Table 1.) 
 
Country Non-melanoma skin 
cancers (w/m) 
Lung cancer 
(w/m) 
Colon cancer 
(w/m) 
Breast cancer 
(w) 
Finland 399 / 416 20 / 55 43 / 41 137 
Switzerland 433 / 560 26 / 78 54 / 75 137 
Netherlands 402 / 470 29 / 92 57 / 62 130 
United Kingdom 458 / 471 51 / 83 55 / 66 135 
USA 459 / 534 59 / 84 55 / 60 144 
Australia 403 / 483 27 / 57 58 / 67 114 
Poland 320 / 382 23 / 104 40 / 41 73 
Table 1. Incidence rate for selected neoplasms based on  Globocan 2002 (number of detected 
cases/year/100 000 citizens) (Global Cancer Statistics Globocan, 2002). 
Epidemiology of skin cancer unanimously indicates that it is a significant global problem. 
However, this problem is not noticed and is underestimated especially because of the fact 
that mortality related with these neoplasms is low (in the USA 1000-2000 patients/year) 
(Jemal et al., 2003) and that this neoplasm is not listed in incidence records (data are not 
complete.) The importance of this problem is mainly affected by the number and dynamics 
of new cases, a high recurrence rate (even 18%) (Silverman et al., 1991) and generally high 
costs of treatment (in the USA the costs of treating skin cancers were more than one billion 
dollars in 2004) (Bickers et al., 2006). 
3. Etiopathogenesis 
Although currently several factors are suspected to be responsible for BCC the most 
important roles in cancerogenesis are played by UV radiation and advanced age of patients. 
They account for more than 90% of neoplastic lesions (Taylor, 1990). 
3.1 Aetiological factors 
Solar radiation (UV) can be divided into three parts depending on the wavelength: UVA 
(wavelength of 320-400 nm), UVB (wavelength of 280-320 nm) and UVC (wavelength of 200-
280 nm) (Kordek et al., 2004). 
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The majority of radiation emitted by the Sun is absorbed by the ozone layer of the 
atmosphere, and consequently, only a low amount reaches the Earth. As due to atmosphere 
pollution the thickness of the ozone layer is gradually reduced, more and more UV radiation 
reaches the Earth, therefore the incidence of BCCs can increase (Goldsmith, 1996). This 
phenomenon may also explain the fact that this neoplasm occurs in younger and younger 
patients as they earlier achieve a cancerogenesis threshold of Average Accumulated 
Exposure (The Skin Cancer Foundation, 2008). 
Exposure to UVB radiation contributes to the BCC development the most (Boukamp, 2005). 
Contrary to common opinions short-term but intensive and long-term but less-intensive 
exposure are equal (Marks et al., 1990). The dose of UV absorbed in the childhood does not 
contribute significantly to neoplasm pathogenesis according to the latest reports (Godar et 
al., 2003). 
Long-term UVB actions lead to the formation of mutagenic photoproducts that damage 
DNA chains in skin cells. DNA damaged in this way is repaired within 24 hours as a result 
of the effective repair system called NER (nucleotide excision repair system) (Szepietowski 
et al., 1996). Impairment of this system present in patients with xeroderma pigmentosum 
inevitably leads to multifocal skin cancer and death at a young age. 
Apart from damage to DNA of skin cells UV radiation also causes mutations in a suppressor 
gene of the p-53 protein. The protein coded by this gene has anti-oncogenic properties as it 
induces apoptosis in the cells with damaged DNA. As a result of a mutation in this gene the 
anti-oncogenic properties of the p-53 protein are turned off, therefore the cells with 
damaged DNA proliferate without control. The presence of a mutation in the p-53 gene is 
found in 60-100% of cases of skin cancer (Marks, 1995). 
The skin inflammatory response induced during the exposure to UV also participates in the 
process of damaging DNA (Maeda & Akaike, 1998) inducing disturbances of division and 
mutations in newly produced cells (Hendrix et al., 1996). 
The sources of UV radiation include not only solar radiation but also PUVA lamps used to 
treat psoriasis and albinism as well as tanning lamps. 
Due to the fact that tanning lamps are widely accessible and due to fashion trends they have 
become especially important in BCC etiopathogenesis in the last years. Some of these 
modern tanning lamps may emit radiation doses which are even 12 times higher than the 
ones emitted by the Sun (11th ROC: Ultraviolet Radiation Related Exposures, 2008). The risk 
of BCC in subjects using tanning lamps regularly is twice the risk observed in the general 
population (Karagas et al., 2002). 
The significance of solar radiation in BCC pathogenesis is emphasised by the fact that this 
neoplasm is found on the skin areas with the most exposure to sunlight, such as the head 
and neck (85% of all lesions, including 30% within the nose (DeVita et al., 2001; McCormack 
et al., 1997). 
It is claimed that such substances as arsenic, wood tar, gas pitch, synthetic antimalarial 
agents or psoralens participate in BCC cancerogenesis (Kordek et al., 2004). 
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3.2  Risk groups 
Age. A peak in the incidence is between 60 and 80 years of age. More than 95% of patients 
are patients above 65 years old (Kordek et al., 2004) although recently it has been observed 
that the incidence in the population below 40 years old is growing (The Skin Cancer 
Foundation, 2008). With age the total period of UV radiation exposure (Average 
Accumulated Exposure) increases, therefore when a given threshold is exceeded 
cancerogenesis processes are initiated. Moreover, the reduced immunity and reduced DNA 
repair and regeneration properties occurring in the elderly also contribute to the increasing 
incidence of BCC in this age group (Pietrzykowska-Chorążak, 1978). 
Sex. Men slightly more frequently suffer from BCC (M/F ratio 1.2) (Brodowski & 
Lewandowski, 2004). It is probably associated with higher exposure to UV radiation what is 
a result of different working conditions (usually outdoors) and rarer use of sun screens in 
the case of men (McCarthy et al., 1999). It should be noted that during the last 30 years the 
rate of women below 40 years of age suffering from BCC has tripled (The Burden of Skin 
Cancer, 2008). 
Race. People with fair skin type, light blue and grey eyes and with light red and fair hair 
suffer from BCC more frequently than people with dark skin (Gloster & Neal, 2006; 
Jabłońska & Chorzelski, 2002; McCarthy et al., 1999). 
Fair hair, frequent sunburn and freckles in the childhood are features which are especially 
associated with BCC development (Bouwes et al., 1996). 
Previous BCC treatment. After the first case of BCC in one’s life the probability of the second 
one increases ten times (Marcil & Stern, 2000). In 50% of patients with previously diagnosed 
BCC other foci will form within 5 years since the first manifestation (Brodowski & 
Lewandowski, 2004). It is estimated that the likelihood of BCC in such patients is almost 140 
times higher that the one in the general population (Aston et al., 1997) 
Post-organ transplant patients. In post-organ transplant patients BCC is the most frequent 
neoplasm and accounts for 35% of all neoplasms occurring in this group of patients. It is 
estimated that post-organ transplant patients suffer from BCC 65-250 times more frequently 
than the general population. BCC most frequently occurs in patients after heart and renal 
transplantation (Jensen et al., 1999). 
Higher incidence of BCC in this group is associated with long-term immunosuppressive 
therapy that reduces the number of CD4+ cells (Viac et al., 1992).  
The pharmacological immunosuppression combined with UVB radiation that additionally 
reduces the number of Langerhans cells (immune properties)  leads to increased 
immunosuppression in the skin and increases the risk of neoplasm (Parrish, 1983). 
Leukaemic patients due to immune system dysfunctions are the next group at a risk. BCC 
most frequently occurs in patients with chronic lymphocytic leukaemia (8-13 times more 
frequently than in the general population) (Manusow & Weinerman, 1975). 
Other risk groups. According to recent opinions risk factors that have not been so widely 
studied include genetic predisposition (Gailani et al., 1996; Gilbody et al., 1994; Schreiber et 
al., 1990), freckles (Gilbody et al., 1994) and rich-fat diet (Zak-Prelich et al., 2004) which is 
low in antioxidants and vitamins (Jeacock, 1998). 
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3.3 Precancerous lesions 
Precancerous lesions are morphologically changed tissues (a pathological process) on the 
basis of which neoplasm develops more frequently than in other unchanged tissues (Kordek 
et al., 2004). 
BCC most frequently develops in the skin without previous lesions. It can significantly more 
rarely (contrary to SCC) develop on the basis of precancerous lesions. Precancerous lesions 
leading to BCC development include:     
 post-radiation dermatitis is most frequently induced by X-ray radiation and is 
characterised by irregular skin thickening accompanied by discolouration, 
hyperpigmentation, teleangiectasia and scared atrophy (Jabłońska & Chorzelski, 2002). 
  It is estimated that in 60% of cases it transforms into BCC (Aston et al., 1997). 
 nevus sebaceous of Jadassohn is a superficial, protruding, yellow-pink, irregular 
nonhairbearing lesion on the head or neck. Its diameter rarely exceeds 3 cm. It is very 
frequently present since birth or early childhood and the likelihood of its 
transformation into BCC is 15% (Aston et al., 1997) . 
 actinic keratosis is characterised by multifocal, dry, yellow-brown, slightly protruding 
keratic build-up, sometimes brown spots are present, they are often numerous on the 
forehead and temples (Jabłońska & Chorzelski, 2002). The risk of neoplastic 
transformation into BCC is 10% (1/1000/year) (Chicheł & Skowronek, 2005). 
 chemical keratosis is a result of exposure to arsenic or wood tar. 
 xeroderma pigmentosum is present in patients with a defective system of DNA repair 
(NER) what leads to the development of multifocal skin cancer and death at a young 
age (Marks, 1995). Lesions resemble intensified freckles and the skin shows atrophy, 
discolouration and teleangiectasia (Jabłońska & Chorzelski, 2002). 
 other rarer precancerous lesions include inflammatory changes with scars and 
hypertrophied scars after burn injuries (Jabłońska & Chorzelski, 2002). 
Although in the majority of patients with BCC it is possible to find at least one of the above 
factors it has to be remembered that the risk of BCC development increases in proportion to 
the number of existing risk factors. 
For example, in Australia the incidence of this neoplasm is the highest. The reason for that is 
the fact that this continent is located close to the equator (much sunlight and UV radiation), 
its population has fair skin type (emigrants from England and Scotland) and the ozone layer 
above Australia is gradually decreasing (Marks et al., 1993). 
4. Clinical picture 
Diagnosis of BCC basing on the clinical picture is associated with many problems. Diagnosis 
precision among experienced dermatologists ranges from 50% to 70% (Kricker et al., 1990; 
Presser & Taylor, 1987). The sensitivity of a clinical test is estimated to be 56-90%, and its 
specificity 75-90% depending on physician’s experience (Mogenses & Jemec, 2007). 
Diagnostic accuracy is enhanced by good lightning, magnification and dermatoscope 
(Costantino et al., 2006). 
Based on the data presented above it can be concluded that BCC diagnosis basing only on a 
clinical picture is difficult and depends on physician’s experience to a large extent. It is often 
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the case that a lesion previously diagnosed as a benign lesion turns out to be BCC following 
a biopsy and the reversed situation is also common. BCC diagnosis basing on the clinical 
picture is not of significance in the diagnostic process. A histopathological examination is 
the only test that can verify and complete the BCC diagnosis. 
Several clinical forms of BCC are traditionally distinguished due to various clinical pictures 
and biological features. 
It has to be emphasised that the awareness of their existence may only help distinguish 
oncologically suspicious lesions, and not diagnose them. 
4.1 Clinical forms of BCC (pict. 1) 
Nodular BCC (BCC nodosum) (pict. 1a)- This is the most common form of BCC. Its 
dimensions may range from several millimetres to 1 cm. It is mainly present in the elderly 
and develops for years. It has a form of a non-inflammatory, glistening nodule or papule 
with pearly appearance. The bigger it is, the more pearly it becomes and present capillaries 
are more and more visible, their layout is radial and they form telangiectasias. The skin 
covering a nodule is very often so thin that even the smallest trauma causes bleeding and 
ulceration. Repetitive ulceration leads to the formation of a basin in the middle (BCC partim 
exulcerans) surrounded by an edge consisting of transparent nodules similar to pearls.44 In 
its central part clusters with discolouration suggesting melanoma may be visible. In rare 
cases tenderness occurs. Small nodules that are difficult to distinguish from seborrhoeic 
warts, moles or psoriasis are a diagnostic problem. Differential diagnosis has to take SCC 
into account; however, it is darker and lacks a pearly edge, horizontally branching 
telangiectasias and clusters with discolouration. Lupus tuberculosis is different from 
nodular BCC in that it has lupus nodules in a scar and lacks a pearly edge; whereas chronic 
lupus erythematosus can be distinguished by the presence of more advanced inflammation, 
perifollicular hyperkeratosis and lacks disintegration (Bers & Berkow, 2001; Jabłońska & 
Chorzelski, 2002).  
Pigmented BCC (BCC pigmentosum) - it is an intensely pigmented variant of a nodular 
form. Differential diagnosis should consider pigmented naevus which is different in that its 
dimensions do not grow and it lacks a characteristic edge. On the other hand, melanoma 
grows faster and more frequently occurs in young patients, with dark hair and dark eyes. 
(Jabłońska & Chorzelski, 2002; The Skin Cancer Foundation) 
Ulcerating BCC (BCC exulcerans, ulcus rodens) (pict 1c, 1d) is an ulcer with prominent, 
heaped-up edges, that tends to bleed and infiltrate stroma. It may penetrate deeply and 
cause damage to the muscles, cartilage, bones or even eye protective apparatus (rodent 
ulcer.) It is distinguished from SCC by the presence of a pearly fold and slower course 
(Jabłońska & Chorzelski, 2002; Raasch & Buettner, 2002).  
Morphoeic or sclerosing BCC ( BCC morpheiforme) (pict. 1f) is an aggressive variant of BCC 
and resembles foci of systemic sclerosis. It is most frequently located on the face and has a 
form of a yellow-white lesion not subject to disintegration, with ill-defined borders. In its 
central part sclerosis, scarring and telangiectasias are often present. It may grow fast and 
reach several centimetres within a few months or remain unchanged for many years. Due to 
ill-defined borders and infiltrations reaching even 7 mm outside a macroscopic border this 
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type of BCC is often resected incompletely and is associated with a high risk of recurrence 
(Jabłońska & Chorzelski, 2002, Wagner & Casciato, 2000). 
Cystic BCC (BCC cysticum) (pict. 1 b) has a form of small, transparent nodules located on 
the eyelids (Jabłońska & Chorzelski, 2002)   
Superficial BCC (BCC superficiale) (pict. 1 e)is a type of BCC that grows especially slowly 
(months and years, often regression.) It occurs more often in young patients and its form 
includes numerous, flat, glistening, light pink lesions with well-defined borders, 
surrounded by a slightly prominent edge. Recent studies regarding a microscopic 3D 
analysis indicated that different lesions are connected what proves their origin from one 
focus (Wade & Ackerman, 1978). 
Photo 1. Clinical forms of BCC
A - nodular BCC
C - ulcerating BCC
E - superficial BCC
B - cystic BCC
D – rodent ulcer
F – morphoeic BCC
 
Photo 1. Clinical forms of BCC 
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Contrary to other variants this type of BCC is not located on the face, but mainly on the 
trunk and limbs, what suggests that its cancerogenesis threshold due to UV radiation is 
lower (McCormack et al., 1997). Its characteristic feature is the fact that the intensity of 
reddening increases when a lesion is stretched and rubbed. When a lesion is stretched, its 
glistening surface is visible, and it may show a peripheral, pearly ring or pearly islets inside 
a lesion. Such lesions are rarely itchy, they rarely bleed or form ulcers. They may be formed 
after arsenic intoxication and coexist with other types of BCCs. Frequently they are mistaken 
for Bowen’s disease and they can be distinguished from it by the presence of glistening 
surface, lack of hyperkeratosis and a lighter shade. Some lesions may be similar to psoriasis, 
pigmented lichen planus, eczema, fungal infections, solar keratosis or even amelanotic 
melanoma (Australian Cancer Network Management of Non-Melanoma Skin Cancer 
Working Party, 2002; Jabłońska & Chorzelski, 2002; The Skin Cancer Foundation)  
Fibroepithelial BCC (fibroepithelioma) is single or multiple reddish nodules, often 
pedunculated, located mainly on the back. They resemble fibroma from a clinical point of 
view (Aston et al., 1997; The Skin Cancer Foundation). 
Basal cell nevus syndrome (Gorlin syndrome) is an autosomal dominant hereditary disorder 
the mutation of which is located in the chromosome 9. Its characteristic features include 
multiple BCCs coexisting with such abnormalities as palmoplantar pits, skin cysts in the 
mandible, bifid ribs, calcification of the dura, mental impairment (Aston et al., 1997). 
Linear basal cell nevus occurs in the form of several streaks consisting of brownish nodules. 
Contrary to Gorlin syndrome which is clinically similar this disorder is not hereditary and 
not associated with abnormalities. It is the rarest variant of BCC (Aston et al., 1997). 
In conclusion, the diagnosis of BCC based on the clinical picture is not an easy task, 
therefore each skin lesion exhibiting some dynamic features, namely growing when 
compared to adjacent structures, with inflammatory changes, bleeding or crusted should be 
treated as potentially neoplastic and requires further diagnostics. 
4.2 Clinical course  
The clinical course of BCC is not characteristic and cannot be predicted: a lesion may not 
change for years, it may grow slowly or extremely fast, infiltration area may enlarge or 
recede, it may also ulcerate or tend to heal (Franchimont, 1982). The tendency to heal may 
lead to decreased vigilance of a physician and their patients, what can be the reason why 
patients with advanced neoplasia (Table 2.) often report at clinics. 
BCC is a locally malignant neoplasm and infiltrates tissues in a three-dimensional fashion, 
forming fingerlike outgrowths not visible to a naked eye originating from the central part of 
a tumour (Braun et al., 2005). Their course and range are unpredictable, therefore it is 
extremely difficult to excise a lesion completely (Raasch & Beuttner, 2002). In the most 
dangerous cases the infiltrate may spread to the dura, bones, nerves and vessels 
(Franchimont, 1982). 
BCC metastasises really rarely as a result of developed extracellular matrix and preserved 
epithelial basement membrane (Jabłońska & Chorzelski, 2002). In 1894-2004 only 268 such 
cases were described, what is less than 0.1% (Ionesco et al., 2006; Weedon & Wall, 1975). 
Metastases were mainly in patients with a long medical history and after radiation therapy 
www.intechopen.com
 Current Concepts in Plastic Surgery 22
(Domarus & Stevens, 1984), with histopathologically aggressive BCC located in the central 
face or near the ear (Randle, 1996) and lesions were larger than 2 cm (>3 cm -2% risk of 
metastases, >5 cm - 25 %, >10 cm-50%) (Snow et al., 1994) BCCs the most frequently spread 
along lymphatic vessels and its metastases were mainly observed in the lymph nodes, lungs, 
bones, pleura, spleen and brain (Safai & Good, 1977). 
Mortality due to BCC is low and mainly regards people older than 85 years and patients 
who did not consent to surgical treatment (Weinstock et al., 1991).  
 
TNM Staging System for Non-melanoma Skin Cancer 
T0 No evidence of primary tumour Nx 
Regional lymph nodes cannot 
be assessed 
Tis Carcinoma in situ N0 
No regional lymph node 
metastasis 
T1 
Tumour 2.0 cm or less in greatest 
dimension 
N1 
Regional lymph node 
metastasis 
T2 
Tumour more than 2.0 cm but not 
more than 5.0 cm in greatest 
dimension 
Mx 
Presence of distant metastasis 
cannot be assessed 
T3 
Tumour more than 5.0 cm in greatest 
dimension 
M0 No distant metastasis  
T4 
Tumour infiltrating anatomical 
structures located under the skin such 
as bones, cartilage, skeletal muscles 
etc. 
M1 
Distant metastasis present 
(includes distant lymph nodes) 
 
 
 
Staging 
 T N M 
0 Tis N0 M0 
I T1 N0 M0 
II T2 or T3 N0 M0 
III 
T4 
Each T 
N0 
N1 
M0 
M0 
IV 
Each 
T 
Each 
N 
M1 
Table 2. Classification TNM and stages of skin cancers based on AJCC 2002 (AJCC, 2002)  
5. BCC diagnostics 
5.1 Invasive diagnostics (biopsy) 
Despite the fact that clinical features are well described and relatively specific, it should be 
emphasised that only a result of a histopathological examination can confirm the diagnosis 
and a biopsy is the gold standard in BCC diagnostics. Some specialists recommend to 
perform a biopsy in all cases when BCC is suspected. Others recommend it only in 
diagnostically doubtful cases or when a histological type can affect the choice of a 
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therapeutic method and prognosis (Costantino et al., 2006). There are following types of a 
biopsy: 
Curettage – involves removing neoplastic tissue using a special spoon. Due to the fact that 
the internal structure of curetted tissues is lost this method is not reliable and currently not 
recommended (Australian Cancer Network Management of Non-Melanoma Skin Cancer 
Working Party, 2002). 
Shave biopsy – involves cutting the half-thickness skin at a tangent to the skin. It is 
recommended for superficial BCC, especially if a tumour is multifocal, is present in 
regression areas and in the case of recurrent disease. A shave biopsy allows for collecting 
material from a large area. The wound heals fast and leaves no secondary deformations, 
therefore it can be difficult to locate when a patient returns to continue treatment (a biopsy 
site should be marked and photographed.) (Australian Cancer Network Management of 
Non-Melanoma Skin Cancer Working Party, 2002). 
Punch biopsy (trepanobiopsy) – a full-thickness skin fragment with the diameter of 4-5 mm 
is removed with a punch consisting of a metal tube with a sharp edge and a handle. 
It is recommended in diagnostics of lesions located in aesthetically and functionally 
important skin regions (e.g. face.) The repetitive 2-mm punch biopsy may be used to 
determine poorly demarcated neoplasms (Australian Cancer Network Management of Non-
Melanoma Skin Cancer Working Party, 2002). 
Incisional biopsy – involves removing a lesion fragment with a healthy skin fragment of 
usually about 3-4 mm. It is recommended in highly advanced cases and in recurrent disease. 
It allows for the estimation of infiltration depth, which is of special importance before 
radiation therapy (Australian Cancer Network Management of Non-Melanoma Skin Cancer 
Working Party, 2002). 
Excisional biopsy – is a diagnostic and therapeutic method. It is recommended in all cases 
where a defect formed after lesion excision can be sutured without leaving deformities 
(trunk, limbs.) Not only does it provide information regarding final diagnosis but also 
informs about the treatment efficacy (completeness). It involves primary excision of a lesion 
with a margin of clinically normal surrounding tissues. The recommended margin ranges 
from 2 to 8 mm. Unfortunately, it occurs quite often that clinically normal surrounding 
tissues are saved to too large an extent and excision is not complete, and as a result 
neoplastic recurrence is observed (Australian Cancer Network Management of Non-
Melanoma Skin Cancer Working Party, 2002). 
5.2 Imaging diagnostics 
Dermatoscopy includes observing the skin with a dermatoscope consisting of a microscope 
with 10-100x magnification. In addition, a dermatoscope is equipped with an internal light 
source that illuminates the skin at an angle of 20°, therefore the picture is enlarged and its 
resolution is higher. This method is of the greatest importance in the diagnostics of 
pigmented lesions and melanoma. It makes it possible to distinguish melanoma from 
pigmented BCC. According to the Monzi criteria pigmented BCC has the following features: 
lack of pigment network and the presence of one of the following features: maple leaflike 
areas, spoke wheel areas, large gray-blue ovoid nests, large gray-blue globules, 
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telangiectasias with arborisation and ulceration (Menzies et al., 2000). In the case of nodular 
BCC in 82% it is possible to observe branching vessels, and the superficial form has delicate 
and short telangiectasias (Argenziano et al., 2004). 
Imaging tests such as computed tomography or magnetic resonance imaging are used to 
determine the extent of neoplastic infiltration when cartilage, bone, large nerve (Williams et 
al., 2001), eyeball (Leibovitch et al., 2005, Meads & Greenway, 2006) or parotid gland (Farley 
et al., 2006) involvement is suspected. 
Other modern methods are only of academic interest and do not play important roles in 
clinical diagnostics. They include: 
High resolution ultrasound examination (20-100 Hz) allowing for imaging the skin up to the 
depth of even 1.1 mm which may be helpful during evaluation of the depth of lesion 
infiltration (Vogt & Ermert, 2007). 
Optical coherence tomography (OCT) (Olmedo et al., 2006) – the mechanism of action is 
similar to the ultrasound examination; however, infrared light is used instead of 
ultrasounds – it is possible to visualise skin layers, appendages and vessels (Welzel et al., 
1997) ; nevertheless, it is not possible to see the basement membrane or to evaluate the depth 
of infiltration (Welzel et al., 2003). 
Confocal microscopy (RCM, reflectance confocal microscopy and FLSM, fluorescence 
confocal laser scanning microscopy) (Ulrich et al., 2008)- involving the detection of 
endogenous (RCM) or exogenous (FLSM) dye with special light, what makes it possible to 
visualise cells and cell structures with the precision nearly as good as the one of a 
histopathological examination (Swindle et al., 2003a; Swindle et al., 2003b). 
Photodynamic diagnostics (PDD) involves the detection of light (using electromagnetic 
waves) emitted from tissues after fluorescence excitation (Morawiec et al., 2004). 
Spectrometric diagnostics involves differentiation and evaluation of the excitation spectrum 
of healthy tissue and tissues with dysplastic or neoplastic lesions (Sieroń et al., 2007). 
Fluorescence lifetime imaging methods (FLIM) - this time is different for healthy tissues and 
neoplastic tissues (Galletly et al., 2008). 
6. BCC: Therapeutic options 
BCC treatment is managed by physicians of many specialities. Dermatologists often use 
cryotherapy and remove small lesions located on the face and trunk, small eyelid neoplasms 
belong to ophthalmologists, lesions on the nose and ear are resected by ENT specialists, 
whereas dental surgeons remove lesions located in the area of the mouth cavity. Lesions the 
size of which makes it possible to direct closure are also excised by general surgeons and 
even by general practitioners in some countries (Australian Cancer Network Management 
of Non-Melanoma Skin Cancer Working Party, 2002). In the treatment of more extensive 
and advanced BCC cases in order to cover a defect after neoplasm excision it is necessary to 
use different reconstruction methods, what is possible only in specialist centres of plastic, 
maxillary or oncological surgery. 
As there are many specialists managing BCC treatment, there are also numerous and 
different therapeutic options. They can be divided into destructive methods where 
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neoplastic tissue is destroyed and it is not possible to evaluate a histopathological type or 
procedure completeness, and surgical methods involving the excision of neoplastic tissue 
with a margin of clinically normal surrounding tissues. 
Destructive methods include: 
 local immunotherapy using imiquimod-containing ointment that stimulates and 
intensifies a local anti-inflammatory reaction what leads to BCC regression (Marks et 
al., 2001). 
 photodynamic therapy, which uses the fact that some photosensitive substances, 
namely substances absorbing light of specific wavelength accumulate in neoplastic 
tissues. When they are selectively accumulated in the neoplastic tissue the lesion is 
exposed to laser light at the wavelength absorbed by a given photosensitive substance. 
Consequently, the high levels of radiation energy are accumulated in the neoplastic 
tissue and it becomes destroyed (Morawiec et al., 2004). 
 radiation therapy, combining many methods starting from superficial radiation (up to 
170 kV) in the case of lesions with the depth up to 6 mm, to electron beam radiation and 
brachytherapy (Telfer et al., 2008). 
 curettage, which is often combined with other methods such as: coagulation (Reymann, 
1985), imiquimod (Wu et al., 2006), photodynamic therapy (Soler et al., 2001), 
cryosurgery (Nordin & Stenquist, 2002) or surgery (Chiller et al., 2000; Johnson et al., 
1991). 
 cryosurgery, which involves the destruction of neoplastic tissue during one or several 
cycles of freezing using liquid nitrogen (Graham, 1983). 
 CO2 laser is a new therapeutic option still studied in clinical trials (Telfer et al., 2008). 
 local application of fluorouracil (5-FU)-containing ointment, which is a classic 
cytostatic. Further studies are necessary to evaluate its long-term efficacy (Telfer et al., 
2008). 
The destructive methods presented above may be used only in some highly selected cases. 
Appropriate patient qualification combined with experience of a specialist using a given 
therapeutic method may provide good therapeutic effects. 
As BCC, contrary to other malignant neoplasms, is rarely responsible for patient’s death, 5-
year survival as an outcome measure is not justified. For that reason, in order to assess the 
efficacy of BCC treatment the recurrence rate during a 5-year follow-up period is used. 
Moreover, it is necessary to take cosmetic and functional results and treatment comfort into 
account. 
Currently it is difficult to evaluate unanimously which destructive method is the best. It is a 
result of the fact that current literature lacks in prospective trials comparing different 
methods and that the criteria of patients’ qualification are extremely narrow and suitable 
only for individual methods, therefore it is not possible to compare them objectively. It is 
commonly thought that each method is good if it is applied in an appropriate case by an 
experienced specialist. 
Surgical methods include classic excision of a lesion with a margin of clinically normal 
surrounding tissues and Mohs micrographic surgery that involves staged resection of a 
lesion with intraoperational histopathological evaluation of its edges. 
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6.1 Selecting a therapeutic method 
In order to determine the indications for different methods, prognostic factors predicting 
BCC with a high-risk of recurrence have been identified. 
6.2 Prognostic factors 
Tumour site - a significantly higher risk of recurrence compared to the trunk and neck 
(recurrence in 0.5%) was observed for BCC located on the face (lateral canthal region – 43% 
of recurrence, upper lid and eyebrow 33%, nose 19%), ear (24%) and scalp. Some specialists 
think that it is associated with a specifical anatomical structure of the subcutaneous tissue of 
these areas, which creates a risk of deeper invasion (Monney & Parry, 2007). 
Other specialists make attempts to explain a higher risk of recurrence in the central face 
(17.5% of recurrence vs 8.6% for other parts of the face) by the fact that a neoplasm changes 
its way of spreading from horizontal to vertical, what is reflected by the fact that infiltration 
spreads along embryonic connections between facial buds (Włodarkiewicz & Muraszko-
Kuźma, 1998; Wronkowski et al., 1978). 
Based on the risk of recurrence, the following areas can be distinguished: high risk of 
recurrence (H), middle risk of recurrence (M) and low risk (L) (Figure 1.). 
However, it has to be emphasised that the above division into risk areas is based on a series 
of retrospective studies that analysed recurrence sites following surgical treatment. The 
margin of a clinically normal surrounding tissues resected with a lesion was not taken into 
account. 
 
Fig. 1. Recurrence risk areas (Swanson, 1983) 
According to the authors more frequent recurrences in the H zone may be associated with 
the fact that a smaller margin of clinically normal surrounding tissues is applied in these 
face areas. It is a result of the fact that operators are afraid of poor aesthetical and functional 
effects. For example, applying a larger margin in the medial canthal region could deform 
and disturb the functions of the eye protective apparatus. In other risk areas (M or L area) 
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e.g. on the neck or the trunk it is possible to resect lesions with larger margins of clinically 
normal surrounding tissues, what has no significant effects on aesthetical and functional 
results; however, it will significantly increase completeness of excision. 
Tumour size and depth of invasion – the recurrence rate increases with the increasing size of 
a tumour. Depending on a diameter the recurrence rate in a 5-year follow-up period is as 
follows for the following tumour sizes: <1.5cm-12%, >3cm-23.1% (Dubin & Kopf, 1983). In 
other studies: <1cm-3.2%, 1-2cm–8%, >2cm recurrence in almost 1/3 of cases 
(Włodarkiewicz & Muraszko-Kuźma, 1998; Wronkowski et al., 1978). 
Moreover, invasion of structures lying under the skin such as cartilages and bones is 
associated with a higher risk of recurrence. 
The guidelines of National Comprehensive Cancer Network (NCCN), an American 
organisation studying therapeutic algorithms for treatment of neoplasms, combine tumour 
site and size in order to assess the recurrence risk (Diagram 2.) 
Definition of clinical margins – the recurrence risk for lesions with ill-defined clinical tumor 
borders is higher than for lesions with well-defined borders (Rowe et al., 1989). 
Histological subtype of BCC – for some morphological subtypes, e.g. morpheaform, 
infiltrating, micronodular or mixed types, the recurrence risk is higher (Table 3.) (Costantino 
et al., 2006 ; Włodarkiewicz & Muraszko-Kuźma, 1998). 
Lesion excision with a classic margin is incomplete in 6.4% for a nodular lesion, for a 
superficial lesion – 3.6%, for a micronodular lesion – 18.6%, for an infiltrating lesion - 26%, 
for a morpheaform lesion – 33.3% (Mooney & Parry, 2007). Moreover, histological features 
of infiltration, especially perineural and perivascular involvement, are significant risk 
factors of recurrence (Costantino et al., 2006). 
Non-aggressive growth pattern 
 (well circumscribed, low recurrence rate) 
Aggressive growth pattern 
(poor circumscribed, high recurrence rate) 
Nodular subtypes (approx. 50%): 
- nodular-solid 
(nodularis-solidum) 
- nodular-adenoid  
(nodularis adenoides, nodularis cribriforme) 
- nodular-cystic 
(nodularis – cysticum) 
Infiltrating (5-20%) 
(infiltrativum, infiltrative non-sclerosing, 
styloides) 
Morpheaform (approx.5%)  
(sclerodermiforme, morpheiforme, 
morphea-like, sclerosans, sclerotic, 
cicatrisans, infiltrative sclerosing) 
 
Micronodular 
(micronodulare) 
 
Metatypic 
(matatypicum, baso-spinocellulare) 
 
Superficial multifocal (15%)  
(superficiale multicentricum, Arning) 
 
Keratotic 
(keratoticum) 
 
Pigmented 
(pigmentosum) 
 
Fibroepithelial      
(fibroepithelioma, Pinkus tumour) 
Table 3. Clinical-pathological classification of BCC (WHO 2006) and classification based on 
the recurrence risk (Bieniek et al., 2008; Kossard et al., 2006). 
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Recurrent BCC – treatment of recurrent BCC is associated with a significantly higher 
recurrence rate than treatment of primary lesions (Australian Cancer Network Management 
of Non-Melanoma Skin Cancer Working Party, 2002). 
Immunosuppression – is associated not only with a higher risk of BCC in general, but also 
with a higher recurrence rate.39 
BCC in patients after organ transplantation and leukaemic patients constitute a special 
problem. 
Other prognostic factors, which are mentioned more rarely: age <35 years (Boeta-Angeles & 
Bennet, 1998), a reconstruction method after surgical excision (recurrent disease within the 
first year when full-thickness skin is grafted, after two years when split-thickness skin is  
grafted and within 4 years after local tissue transfers) (Koplin & Zarem, 1980; Richmond & 
Davie, 1987). Prognosis for Gorlin syndrome treatment is also poor (Gorlin, 1995). 
The presence or lack of such features makes it possible to divide all types of BCC into high 
or low-risk lesions, therefore it is possible to select an appropriate therapeutic method. The 
latest guidelines for BCC treatment suggested by the British and American Scientific 
Societies are  outlined (Diagram 1 and 2). 
As it can be concluded from the guidelines, all high- and low-risk BCC as well as recurrent 
BCC may be surgically treated. 
 
Diagram 1. Guidelines for BCC treatment based on NCNN Clinical Practice Guidelines in 
Oncology: Basal Cell and Squamous Cell Skin Cancers (USA, 01.2009)  
Surgery is currently the gold standard for BCC treatment because of high efficacy, its 
versatility, fast results, good aesthetical and functional outcome, low risk of complication, 
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availability (the majority of mentioned destructive methods can only be applied in highly 
specialized clinics), low costs of treatment and what is even more important, the possibility 
to evaluate procedure completeness (Bath-Hextall et al., 2007). 
 
Diagram 2. Treatment of BCC based on Guidelines for the Management of Basal Cell Carcinoma 
(UK, 07.2008 r.)   
7. Surgical treatment 
7.1 Surgical excision with a margin of clinically normal surrounding tissues 
Surgical treatment is the simplest, the most effective and nowadays the most popular 
method of treatment. Its efficacy evaluated as the recurrence rate in a 5-year follow-up is 2-
10% (Cullen et al., 1993; Goldberg et al., 1989; Griffiths et al., 2005; Silverman et al., 1992; 
Walker et al., 2006). So far only few prospective studies comparing surgical excision with 
other methods have been published in the literature. 
Thissen compared cryosurgery (spray technique and double cycle of freezing) with surgical 
treatment of nodular and superficial BCC of the head and neck with the diameter of <2cm 
and observed better therapeutic outcomes in surgically treated patients; however, the 
differences were not statistically significant (Thissen et al., 2000). 
On the other hand, Rhodes compared surgical treatment of nodular BCC located on the face 
with photodynamic therapy (PDT.) He did not observe significant differences in recurrence 
rates during the first 3 months; however, in 12- and 24-month follow-up he observed a 
statistically significant increase in the recurrence rate and worse cosmetic results in the case 
of PDT (Rhodes et al., 2004). Taking into account long-term results (after 60 months), 
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recurrence occurred in 14% after PDT and only in 4% after surgical treatment (Rhodes et al., 
2007). 
Moreover, another study where surgical excision of primary BCCs with the diameter below 
4 cm was compared with radiation therapy indicated that during a 4-year follow-up a lower 
recurrence rate was associated with surgical excision (0.7% vs 7.5%.) Moreover, cosmetic 
results after surgical excision were more acceptable than the ones after radiation therapy 
(79% vs 40%), which were associated with discolouration and telangiectasia in more than 
65% and radiodystrophy in 41% of cases (Avril et al., 1997; Petit et al., 2000). 
An important stage in surgical excision of a lesion is the determination of a macroscopic 
(clinical) lesion border. It can be done using magnification (3x at least), Wood’s lamp or 
dermatoscope (Costantino et al., 2006). Applying curettage before excision may increase the 
completeness of a procedure because it may be possible to determine real borders of a 
tumour more precisely (neoplastic tissues are more curettable) (Chiller et al., 2000; Johnson 
et al., 1991). When lesion borders have been precisely determined a margin (range) of 
clinically normal tissue is planned, and they are removed together with a lesion en-block. 
The specimen resected in this way is subject to histopathological evaluation during which a 
histopathological subtype of BCC is confirmed as well as procedure completeness. The 
tissue defect  formed after lesion excision is closed according to the  reconstructive ladder. 
7.2  Margin of clinically normal surrounding tissue 
It is obvious that the extent of neoplastic infiltration affects the range of a peripheral and 
deep margin. On the other hand, the infiltration extent correlates with prognostic factors 
(Telfer et al., 2008) e.g. for primary morpheaform BCC resected with a 3-mm margin only 
66% of radical excisions observed, with a 5-mm margin – 82% and with a 13-15-mm more 
than 95%. For that reason, the presence of prognostic factors should determine the extent of 
a margin. Nonetheless, a precise therapeutic algorithm has so far not been established 
(Telfer et al., 2008). The extent of suggested margins ranges from 2 to 15 mm (Table 4), is 
established empirically and what is the most important, it does not take prognostic factors 
into account.  
As reports published so far are in the majority retrospective reviews of therapeutic 
outcomes for different margins, their conclusions should be treated more like advices rather 
than methodologically proven guidelines.  
Although American recommendations of NCCN (National Comprehensive Cancer 
Network) recommend to remove low-risk BCCs with a 4-mm margin it has to be noted that, 
what is emphasised by the authors of these recommendations, this guideline was based on 
lower-level evidence (Clinical Practice Guidelines in Oncology, 2009). It is based on the 
prospective report by Wolf from 1987 (Table 4) where 117 primary lesions were resected 
with a 2-mm margin with subsequent histopathological evaluation according to Mohs. If 
excision was incomplete, the margin of resected tissues was expanded by 1 mm until the 
procedure was complete. When lesions were excised with 2-mm margins, completeness of 
70% was achieved, with 3-mm margins excisions were complete in 85% of cases and when 
margins were 4 mm completeness was as high as 95%. Although these results are 
statistically significant, they are poorly reliable because the study did not take into account 
prognostic factors that have been identified until now. The study lacks in information 
regarding the site of a tumour, its histopathological subtype and regards only  
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Table 4. Range of excision margin – analysis of selected studies. 
well-demarcated lesions, and in 91% of cases the tumour diameter was below 2 cm, and the 
mean was 9 mm. Due to low reliability of studies published so far the need to perform 
prospective studies according to evidence based medicine (EBM) arises as it is necessary to 
determine unanimously the range of margins depending on prognostic factors. It is of 
special importance when BCCs are located in functionally and aesthetically important face 
areas such as nose (ala nasi, columella, naso-facial sulcus), eyelids, medial and lateral 
canthus, ear  with preauricular and postauricular region, lips philtrum (Chicheł & 
Skowronek, 2005; Mohs & Parry, 2007). All anatomical regions mentioned above are 
associated with a high risk of recurrence ( H -area– Figure 1), and the differences in 
suggested margin  are extremely important although they are as small as several 
millimetres. The excision of a lesion with a larger margin may for example result in the 
removal of lacrimal ducts or cause ectropion. For that reason, during margin selection a 
surgeon resecting a lesion in these areas (a suggested margin for the face is from 2 to 10 mm) 
has to take into account such aspects as post-surgical function preservation, possibility of 
defect closure or, last but not least, achieving acceptable cosmetic results. 
As it can be seen, due to varied and often not very reliable recommendations, the decision to 
choose an oncologically radical margin is extremely difficult and in most cases made based 
on operator’s experience (his knowledge and skills.) 
Prospective trials taking into account all factors affecting the range of a margin (including 
prognostic factors) would systematise the current state of knowledge and contribute to 
establishing consensus regarding the excision margins, what is indispensable in order to 
prepare a consistent algorithm for BCC treatment. 
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The deep margin range is less controversial. The majority of authors recommend to resect 
BCCs at the depth reaching the fat tissue (Telfer et al., 2008). In BCCs where the skin is 
directly above deep tissues (cartilages, bones) it is obligatory to perform imaging tests and if 
necessary, increase the depth of a margin (Australian Cancer Network Management of Non-
Melanoma Skin Cancer Working Party, 2002). 
7.3 Histopathological evaluation 
In order to determine the location of a resected tumour with relation to the adjacent tissues, 
each specimen indicated for a histopathological examination should be equipped with a 
surgical marker (suture, cut, dye mark) and a precise diagram presenting its location with 
relation to the adjacent tissues. As a result, it will be possible to identify sites where excision 
was incomplete. Moreover, information regarding previous treatment and results of a 
biopsy are also necessary (Australian Cancer Network Management of Non-Melanoma Skin 
Cancer Working Party, 2002). 
The aim of a histopathological examination is to determine a histological subtype of BCC 
and excision completeness. 
From a histopathological point of view BCC is similar to the basement membrane cells but 
differs in that the nucleus/cytoplasm ratio is higher. 
Moreover, BCC cells do not have intercellular bridges and mitotic figures (Bader, 2008). 
According to the latest WHO classification there are several clinical-pathological types of 
BCC. It includes criteria of a clinical and histopathological picture of different subtypes of 
BCC (Kossard et al., 2006).   
From a clinical point of view it is important to distinguish histopathological subtypes with a  
aggressive growth pattern, what is of importance when a surgical procedure is planned 
(Table 3.) In addition, infiltration along vessels and nerves is dangerous, and associated with 
a high risk of recurrence (Costantiono, 2006). 
The literature also describes undifferentiated and differentiated BCC. Little or no 
differentiation is reffered to as a solid BCC and includes pigmented, superficial, 
morpheaform and infiltrative subtypes. Differentiated BCC is mainly nodular BCC which 
often differentiates into cutaneous appendages, including  hair, sebaceous or tubular glands 
(Bader, 2008). For statistical purposes the classification including three types is often used: 
nodular (solid), fibrosing (desmoplastic) and metatypic (baso-spinocellular) (Bieniek et al., 
2008). Based on precise histopathological evaluation it was determined that neoplastic 
infiltration is irregular and unpredictable; however, it is usually present to a limited extent 
(Burg et al. 1975). 
The margin of clinically normal surrounding tissues viewed under a microscope is on 
average smaller by 24% from a macroscopic in vivo margin as a result of shrinking and 
fixing (Thomas et al., 2003).  
Hendrix et al. proved that infiltration in the case of infiltrating BCC is on average 7.2 mm, 
whereas for nodular BCC it is 4.7 mm (primary /recurrent  5.6/10.4 vs 4.3/5.7 respectively) 
(Hendrix & Parlette, 1996). On the other hand, according to Salasche primary morpheaform 
BCC can infiltrate tissues even up to the width of 7 mm beyond macroscopic borders of a 
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lesion (Salasche et al., 1981). Based on Burg’s studies microscopic borders of primary BCC 
infiltration are estimated to be 3-6 mm, and 5-9 mm in the case of recurrent disease (Burg et 
al., 1975).  
The most important factor determining the recurrence  is to determine the extent of 
neoplastic infiltration and its relation to the edge of resection (Australian Cancer Network 
Management of Non-Melanoma Skin Cancer Working Party, 2002). It regards cases where 
tumor was identified at peripheral edge of resection and deep edge of resection what is 
associated with a more than a double risk of recurrence (17% peripheral vs 35% deep 
surgical edge in a 5-year follow-up period) (Liu et al., 1991).   
In order to evaluate the risk of recurrence Pascal (Pascal et al., 1986) made the following 
classification:  
 incomplete excision – a tumor is identified at a surgical edge.  It is associated with a 
33% risk of recurrence within 5 years follow-up. 
 suboptimal excision - tumor is visible at the distance smaller than 0.5 mm from a 
surgical edge, what microscopically corresponds to one high-power field (400x.) In such 
cases there is a 12% risk of recurrence within 5 years follow-up. 
 complete excision – tumor is visible at the distance larger than 0.5 mm, namely it is not 
present in one high-power field (400x) involving a surgical edge.  
Although resecting a tumor in these cases is described as complete excision it is associated 
with a 1.2% risk of recurrence within 5 years follow-up. 
It is mainly associated with the fact that histopathological techniques are not perfect. 
Conventional microscoping processing involves vertical sectioning at every 2-4 µm, 
perpendicular to the tumor surface (breadloaf sectioning -recommended for lesions <16 
mm) (Rapini, 1990), when specimens from all four lesion quadrants are resected (cross 
sectioning – recommended >16 mm) (Rapini, 1990) or from its peripheral parts (peripheral 
sectioning) (Mohs & Parry, 2007) (Fig. 2: A, B, C.). Consequently, only representative vertical 
sections are evaluated and it is not possible to evaluate the whole tumor margin. It is 
claimed that using conventional methods it is possible to evaluate only from 0.01% to 44% of 
tumor margins (Kimyai-Asadi et al., 2005; Mohs & Parry, 2007). 
The basic drawback of this method is an assumption that when a tissue margin in 
representative sections is considered as tumor-free, the whole lesion is considered to be 
excised completely. The method suggested by Mohs is significantly more precise than 
conventional techniques as it allows for collecting sections which are horizontal to the tumor 
surface, namely it is possible to evaluate the whole margin (Fig. 2:D.) 
7.4 Incomplete excision 
Incomplete excision of BCC is a situation when a tumor is identified at surgical edge or is at 
the distance of <0.5 mm from it (one high-power field at 400x magnification.) On average 
4.7% - 7% (Griffiths, 1999; Kumar et al., 2000) of cases in the UK and 6.3% in Australia (Dieu 
& Macleod, 2002; Sussman & Liggins, 1996) are excised incompletely. These numbers prove 
that a problem is huge and although factors responsible for an increased risk of incomplete 
excision have already been identified until now it has not been possible to create a consistent 
algorithm of BCC management. The necessity to improve procedure completeness is 
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undeniable; however, management following incomplete excision (follow-up,  reexcision, 
radiation therapy) raises many controversies.  
Followers of  follow-up  base  their  opinions  on  numerous  studies  proving  that  recurrent 
disease will occur only in 30-41% of cases (De Silva & Dellon, 1985; Park et al., 1994; 
Sussman & Liggins, 1996) out of all incompletely excised lesions, so as many as 2/3 of tumor 
tissue left in the skin will not recur. 
 
Fig. 2. Methods of microscopic processing: cross sectioning (A), peripheral sectioning (B), 
breadloaf sectioning (C),  Mohs method (D). 
In addition, prospective studies where incompletely excised BCCs were reexcised  showed 
the presence of tumor tissue only in 45% (Wilson et al., 2004) and 54% (Griffiths, 1999) using 
conventional histopathological evaluation and 55% using the Mohs method (Bieley et al., 
1992). It means that in almost half of cases the tumor tissue which was left regresses, 
possibly with the help of the immune system (Bieley et al., 1992). 
Is a reexcision of an incompletely excised tumor justified? 
Richmond et al. included in their study 92% patients who underwent reexcision of an 
incompletely excised tumors and 90% patients who were only observed (until recurrence 
occur, then it was excised immediately.) After a 10-year follow-up period recurrence 
occurred only in 9% of patients in the first group and in as many as 60% of patients in the 
other (Richmond & Davie, 1987). 
Koplin recommends reexcision only in two cases: when a tumor is identified at surgical 
edge and when a tumor was excised suboptimally; however, only when expected life-time is 
long (Koplin & Zarem, 1980). 
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On the other hand, Robinson recommends only follow-up in the case of incomplete excision 
of an aggressive histopathological subtypes of BCC located on the nose, cheeks, around the 
lips, in men >65 years and in the case when a flap or split-thickness skin graft was used to 
cover a defect. His stand is based on the observation that in cases mentioned above 
significantly longer time is required for recurrence development (>5 years) than in other 
cases of BCC excised incompletely (Robinson & Fischer, 1996). 
Similar controversies are associated with the use of radiation therapy following incomplete 
BCC excision. In a 10-year follow-up Liu compared the number of recurrence in the group of 
patients after immediate post-operative radiation therapy with the group of observed 
patients. Although in the group of patients subject to post-operative radiation therapy the 
recurrence rate was significantly lower the evaluation of all treatment aspects (costs 
analysis, complications) indicated that it is only recommended in cases after recurrence and 
when deep and lateral margins are involved. In the remaining cases the authors recommend 
careful observation stating a high presence of patients on follow-up examinations and 
significantly lower treatment costs as arguments for it (Liu et al., 1991). 
On the other hand Wilson et al. recommend radiation therapy or reexcision of a tumor 
following its incomplete excision when a local flap or full-thickness skin graft was applied 
and when a deep margin in the H zone was involved. In all such cases recurrence would be 
difficult to detect and treat. In addition, Wilson does not recommend radiation therapy in 
young patients, especially in the forehead and scalp due to the risk of neoplastic 
transformation in scarred lesions in a long-term follow-up. In such cases, as well as in the 
cases of histologically aggressive BCC reexcision is recommended (Wilson et al., 2004).  
Some authors have even more restrictive views on radiation therapy and they recommend it 
only in small lesions in patients who do not agree surgical treatment or in whom it is not 
possible to perform a surgery due to their physical condition (Australian Cancer Network 
Management of Non-Melanoma Skin Cancer Working Party, 2002).   
7.5 Recurrence 
Recurrence is defined as a new focus of tumor in a scar or in its vicinity formed after 
excision of a primary tumor occurring within 5 years since the excision and with the same 
histological type as the primary tumor. The incidence rate after surgical treatment of BCC in 
a 5-year follow-up is estimated to be 5% for primary and about 13% for recurrence BCC 
(Hauben et al., 1982). The factors increasing the risk of recurrence have been discussed in the 
Part II. Recurrence is the most frequent, namely as many as 82% of cases occur in the first 
five years, and about 30% of cases are present in the first year of observation, 50% in the 
second and 66% in the third year. The remaining 18% of cases occur in the period from 5 to 
10 years since tumor excision (Marcil & Stern, 2000). The recommended follow-up for one 
patient in order to observe recurrence is 5 years (every 3 months during the first year, then 
every 6 months) (Liu et al., 1991) although the latest guidelines of the American NCCN 
recommend follow-up every 6-12 months for the whole lifetime (Clinical Practice Guidelines 
in Oncology, 2009). During follow-up control  it is necessary to educate a patient with the 
possibilities of active prophylaxis against BCC, especially regarding sun protection. 
Moreover, it is also necessary to inform a patient about the need of skin self-examination. It 
is of special importance not only because of recurrence monitoring but also due to the risk of 
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development of another BCC which is ten times higher in patients with a previous BCC than 
in the general population (Marcil & Stern, 2000). This risk is also significantly higher in 
elderly patients, in patients with multiple BCCs and with the lesion diameter > 1cm (Van 
Iersen, 2005). 
In some countries general practitioners manage follow-up control after BCC excision (Park 
et al., 1994). 
Clinical symptoms that should raise suspicion of recurrence: 
 scarring with non-healing or recurrent ulceration, 
 a scar that is becoming red, desquamating and looks like ichtyosis, 
 an expanding scar with telangiectasia inside the scar  
 a nodule appearing within a scar 
 tissue destruction 
Recurrence following non-surgical treatment (radiation therapy, cryotherapy, curettage) is 
associated with a higher risk of another recurrence or even with the possibility of metastases 
(Smith & Grande, 1991). Skin lesions due to such treatment (atrophy, hypopigmentation, 
scarring) make it difficult to assess the extent of recurrence precisely. In addition, recurrence  
following treating BCC with cryotherapy may be difficult to evaluate due to scarring 
associated with treatment and the fact that infiltration spreads deeply beneath normally 
looking skin (Australian Cancer Network Management of Non-Melanoma Skin Cancer 
Working Party, 2002). Moreover, recurrence diagnostics in skin creases such as the 
nasolabial sulcus may also be a huge problem. Due to diagnostic difficulties in all cases 
when recurrence is suspected it is necessary to perform a biopsy to confirm diagnosis. 
Recurrence treatment is significantly more difficult than treatment of a primary lesion, and 
the success rate is considerably lower (Rowe et al., 1989a). The risk of another recurrence is 
by 50% higher that in the case of a primary lesion (Silverman et al., 1992). Furthermore, it is 
thought that some incompletely excised lesions recur in a more aggressive growth pattern (a 
more aggressive histological subtype), especially in the central face (Boulinguez et al., 2004). 
Surgical methods are recommended to treat recurrence. Wide BCC excision with a scar and 
a margin ranging from 5 to 10 mm or Mohs micrographic surgery which is significantly 
more successful are performed. 
7.6 Mohs micrographic surgery (excision controlled histopathologically)  
The history how this method came into existence and evolved is tightly associated with its 
creator. In 1930s Frederic E. Mohs, who was a medicine student at those times, studied the 
effects of different substances on cancer cells in rats. When he injected 20% zinc chloride 
solution inside a tumour he accidentally observed tissue necrosis and at the same time in 
situ tissue fixation. As a result of in vivo tissue fixation with zinc chloride he was able to cut 
specimens horizontally (parallel to the skin.) As a result he was able not only to assess a 
tumor histopathologically, but also to assess its whole margin, what formed the base to 
excision of tumors under microscopic control. After a short period of laboratory tests Mohs 
replaced 20% zinc chloride solution with the zinc paste applied 24h before tumor excision 
and started clinical trials on the use of his method in the treatment of skin tumors. As early 
as in 1941 Mohs presented his first clinical trials in “Archives of surgery” and named his 
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method chemosurgery (Mohs, 1941) (chemo – as tissue fixation is a result of a chemical 
reaction between  tissues and zinc chloride) (Diagram 3). 
It involves curettage of a tumour then applying a thick layer of the zinc paste under 
occlusive dressing which increases paste penetration and protects the surrounding skin. In 
the case of tumors with large hyperkeratosis before applying the zinc paste dichloroacetic 
acid with the keratolytic effects can be used and as a result, after the keratotic layer has been 
exfoliated, penetration of the zinc paste is greater. Tissues prepared in this way become 
necrotic after 6-24 hours what creates appropriate conditions for a surgical procedure (no 
pain, small bleeding at the operation site.) During the first stage a surgeon uses methylene 
blue, sutures or incisions to mark landmarks that will allow further identification of tumor 
areas that have been excised incompletely. Then the whole tumor with a 3-mm margin of 
clinically normal surrounding tissues is excised at the angle of 45º, what makes it possible to 
“tease up” a epidermal edge and facilitates histopathological evaluation, especially of 
superficial skin layers. The incision is continued at the angle of 45º around the tumor, and 
the deep surgical edge is parallel to the skin. After haemostasis a diagram presenting a 
defect formed after tumor excision and its relation to previously marked landmarks is 
prepared. 
In the next stage, a histopathologist divides a lesion according to landmarks marked by an 
operator (usually into 4 quadrants), turns it deep surface up and marks edges of all 
quadrants formed after the division with two different dyes. Consequently, further 
identification of specimen areas excised incompletely is made easier. After marking 
quadrant edges the specimen is sectioned parallel to the skin and as a result 5-7 μm sections 
are obtained, therefore it is possible to assess the whole lesion margin. When a tumor 
fragment is found in the close vicinity of a surgical edge (suboptimal excision) or when a 
tumor is identified at surgical edge (incomplete excision) a histopathologist marks an area of 
incomplete excision in the diagram. Based on this diagram a surgeon locates the area with 
tumor cells that has been left, and then the whole process of fixation, excision and 
histopathological evaluation is repeated until complete excision is obtained. 
In some cases when lesions were excised incompletely the whole process was repeated 
several times, what due to long time of tissue fixation with the zinc paste (6-24h) took even 
several days (high costs of treatment and hospitalisation.) Moreover, application of the zinc 
paste was painful for patients and induced tissue necrosis and ulceration in the lesion 
vicinity. 
Therefore after tumor excision it was necessary to wait until necrosis areas became defined, 
and only then it was possible to close formed defect. All these features resulted in the fact 
that despite high efficacy this method did not gain much popularity. However, Mohs, who 
believed in the success of his method, focused more on its promotion than improvement. 
And in 1953 when he was doing a film demonstrating his technique an accident decided 
about a breakthrough discovery for yet another time. Mohs during resecting BCC of the 
lower eyelid omitted the stage of tissue fixation with the zinc paste in order to accelerate the 
whole process for the purposes of the film. Instead he excised BCC under local anaesthesia, 
then froze it and using cryotome obtained horizontal specimens of 5-7 μm. After their 
standard staining with haematoxylin-eosin he stated than the quality of specimens obtained 
in this way is the same when compared to the original method, and the duration of the 
procedure, costs and lack of ulceration and pain are significantly lower. Moreover, primary 
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defect closure was possible what decided about the success of this method to a large extent. 
With time the fresh-tissue technique replaced the fixed-tissue technique that was originally 
developed by Mohs. The original name of the whole procedure (chemosurgery) was 
replaced by Mohs Micrographic Surgery (MMS) due to unfavourable associations and in 
order to confer its meaning, namely mapping out of the specific location  of tumor extension 
by the use of microscopic evaluation.  
 
Diagram 3. Mohs micrographic surgery 
Currently the fixed-tissue technique is used only in selected cases, mainly in order to 
eliminate excessive bleeding during lesion excision in areas which are well supplied with 
blood (e.g. penis.) The fresh-tissue technique has considerably more indications in BCC 
treatment (Table 5.) 
A review of studies published since the mid-1940s confirms the high efficacy of this method 
reaching even 99% in a 5-year follow-up for primary (Rowe et al., 1989b) and 94.4 % for 
recurrent BCC (Rowe et al., 1989a). In prospective trials conducted in Australia in 819 
patients with periocular BCC no recurrence were observed in 100% patients with primary 
and in 92.2% with recurrent BCC (Malhotra et al., 2004) in a 5-year follow-up, and in another 
study with 3370 patients with BCC on the head and neck no recurrence were observed in 
98.8% patients with primary BCC and in 96% with recurrent BCC in a 5-year follow-up 
(Leibovitch et al., 2005).  
Apart from its high efficacy other advantages of this method include the minimum amount 
of excised tissues and the possibility of primary defect closure knowing that a lesion was 
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excised completely. Despite many advantages Mohs Micrographic Surgery has been fully 
approved only in the USA, where it is used in about 30% of cases (Gaston et al., 1999). 
 
Indications for Mohs Micrographic Surgery: 
 location: H area (Part II), especially in the areas where it is necessary to excise a lesion 
in a saving manner (tip and ala of the nose, lips, eyelids, ear, hands, feet, genitalia) 
 
 size: lesion with the diameter > 2 cm 
 
 histopathological subtype: BCC with an aggressive growth pattern (tab.4), perineural, 
perivascular or   deep tissues involvement  
 
 recurrent BCC  
 
 BCC in  patients with immunosuppression  
 
 BCC in  patients with a history of previous radiation therapy  
 
 long-lasting BCC (neglected)  
 
 Gorlin syndrome 
Table 5. Indications for Mohs Micrographic Surgery (at least one of the mentioned above) 
(Mohs & Parry, 2007). 
Also in the USA was formed  the American College of Mohs Micrographic Surgery and 
Cutaneus Oncology that currently has more than 800 physicians of different specialities who 
are qualified to use this method when they have completed a 1-2 year training course. In 
other countries Mohs micrographic surgery is used more rarely, mainly due to high costs 
(equipment, service, qualified staff) (Cook & Zitelli, 1998) and more work contribution 
(Hsuan et al., 2004) (time of one procedure is 3h on average) compared to traditional 
surgical lesion excision. Moreover, contrary to a classic surgical procedure this method is 
laborious, time-consuming and exhausting for a patient. 
Some researchers defend high costs of treatment using this method by the fact that it is 
possible to obtain better results, consequently, it is more effective in terms of treatment costs 
than classic surgery (Hsuan et al., 2004). However, Smeets in a prospective trial comparing 
this method with surgical excision of a lesion with a 3-mm margin of clinically normal 
surrounding tissue following 30 months of follow-up did not find statistically significant 
differences in the treatment efficacy between these two method (Smeets et al., 2004). 
8. Conclusion 
BCC is one of the most common human malignancies. Epidemiology and the increasing rate 
of incidence prove that BCC is and will be in the future a significant clinical problem. 
Studies published recently complete our knowledge on its pathogenesis and present new 
diagnostic and therapeutic methods. The majority of new therapeutic methods may be used 
only in highly selected cases. 
www.intechopen.com
 Current Concepts in Plastic Surgery 40
The only universal method that can be used to treat all cases of BCC is surgical excision with 
a margin of clinically normal surrounding tissues. However, despite numerous advantages 
of this method and its versatility it has been impossible to determine until now what margin 
of clinically normal surrounding tissue should be applied when BCC is excised. It is of 
special importance when lesions in functionally and aesthetically important face areas are 
excised. In such cases margin differences as low as 1 mm may affect completeness of 
excision, its functional results, the method of reconstruction and its aesthetic results as well. 
For that reason, the authors think that prospective studies in accordance with EBM are 
necessary in order to determine unanimously the range of margins depending on the 
prognostic factors mentioned above. 
The results of such studies could allow for the unanimous determination of the excision 
margins and preparing a consistent and common algorithm of BCC treatment. 
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